Health Sector Budget 2026 Introduces Strategic Biotech Enhancements
Key Takeaways
The Union Budget 2026–27, presented by Finance Minister Nirmala Sitharaman, has unveiled a transformative ₹10,000 crore initiative aimed to revolutionize India’s biopharmaceutical landscape. Dubbed the "Biopharma SHAKTI" program (Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation), this five-year plan aspires to position India as a global leader in biologics and biosimilars manufacturing, signaling the country's decisive pivot toward innovation-driven healthcare.
Biopharma SHAKTI: A Global Ambition
India’s healthcare sector has long been synonymous with affordable generic medicines, but the Biopharma SHAKTI program seeks to transition the nation into an innovation hub for advanced therapies. A dedicated outlay of ₹10,000 crore will support the creation of an end-to-end ecosystem for biologics and biosimilars – the fastest-growing segment of the global pharmaceutical market.
Key components of the initiative include:
- Strengthening the Central Drugs Standard Control Organization (CDSCO) with a dedicated scientific review cadre to meet global regulatory standards and enable faster approvals.
- Establishing 1,000 clinical trial sites to enhance India’s clinical research infrastructure and credibility.
- Expanding the National Institutes of Pharmaceutical Education and Research (NIPER) network from seven to ten institutes, focusing on biologics manufacturing, regulatory science, and quality assurance.
sbb-itb-8f61039
Cancer and Rare Disease Drug Relief
To ease the financial burden on patients, the government has also announced a full exemption of basic customs duty on 17 critical cancer drugs, alongside seven drugs for rare diseases included under import duty exemptions for personal medical use. This move is expected to significantly improve access to advanced therapies.
Kiran Mazumdar-Shaw, Chairperson of Biocon, lauded the initiative, stating, "By placing biopharma among the seven strategic frontier sectors and launching Biopharma Shakti with an outlay of ₹10,000 crore over five years, the Union Budget makes a decisive investment in India’s health and innovation future. As India’s disease burden shifts toward cancer, diabetes, and autoimmune disorders, biologics and biosimilars will be central to improving longevity and quality of life."
Expanding Healthcare Access and Workforce Development
The Budget also places a strong emphasis on expanding healthcare access and preparing a future-ready workforce. The government plans to train 1.5 lakh caregivers and add 1 lakh allied health professionals over the next five years by upgrading existing institutions and establishing new ones. These efforts will address critical gaps in diagnostics, rehabilitation, and specialized care, particularly as India’s elderly population grows.
Gautam Khanna, CEO of P.D. Hinduja Hospital, remarked, "The announcement to add 1 lakh allied healthcare professionals… alongside training 1.5 lakh caregivers, will go a long way in creating a comprehensive geriatric and allied care system… This futuristic measure will help in easing the lives of our senior citizens."
The expansion of medical education is further reinforced with the addition of 75,000 new medical seats and the establishment of new mental health institutions in Ranchi and Tezpur.
Industry Reactions and Next Steps
Health industry leaders have broadly welcomed the Budget’s focus on biopharma innovation and healthcare access. Rajiv Nath, Forum Coordinator at the Association of Indian Medical Device Industry (AiMeD), emphasized, "Budget’s emphasis on strengthening the Central Drugs Standard Control Organisation (CDSCO) through dedicated scientific review capacity, domain specialists, and time-bound approvals… [is] essential for regulatory predictability, global alignment, and investor confidence."
Meanwhile, Satish Reddy, Chairman of Dr. Reddy’s Laboratories, noted the significance of the biopharma push, saying, "The ₹10,000-crore Biopharma Shakti programme will be a key enabler for India’s journey from volume to value leadership… alongside the expansion of the national clinical trials network and strengthening of the CDSCO with specialised scientific review and globally aligned timelines."
The healthcare sector has also received an overall allocation of ₹1,05,530 crore, including measures to bolster mental health, trauma care, and regional medical hubs. This holistic approach is expected to strengthen India’s healthcare infrastructure while simultaneously creating new opportunities for employment and innovation.
Conclusion
The 2026 Union Budget marks a pivotal moment for India’s healthcare and pharmaceutical industries, with the Biopharma SHAKTI program at its core. By fostering innovation, expanding access to critical medicines, and building a skilled workforce, the government has laid the foundation for a more robust, resilient, and globally competitive healthcare ecosystem. As the initiative unfolds, all eyes will be on India’s ability to execute these ambitious plans and cement its position as a global leader in healthcare and biopharma innovation.
Author
